PROCESS FOR THE PREPARATION OF 3ß-HYDROXY-17-(1H-BENZIMIDAZOL-1-YL)ANDROSTA-5,16-DIENE
    1.
    发明申请
    PROCESS FOR THE PREPARATION OF 3ß-HYDROXY-17-(1H-BENZIMIDAZOL-1-YL)ANDROSTA-5,16-DIENE 审中-公开
    制备3β-羟基-17-(1H-苯并咪唑-1-基)ANDROSTA-5,16-二烯的方法

    公开(公告)号:WO2018029223A1

    公开(公告)日:2018-02-15

    申请号:PCT/EP2017/070124

    申请日:2017-08-08

    Abstract: A process for the synthesis of β-hydroxy 3-17-(1H-benzimidazol-1-yl)androsta-5,16-diene is described, a compound also known as Galeterone and used in the treatment of prostate cancer, having the formula (6).

    Abstract translation: 描述了一种合成β-羟基3-17-(1H-苯并咪唑-1-基)雄甾-5,16-二烯的方法,该化合物也称为Galeterone并用于 治疗前列腺癌,具有公式(6)。

    PROCESS FOR THE PREPARATION OF DROSPIRENONE AS A FINE POWDER THROUGH A DOUBLE CHANGE OF CRYSTALLINE FORM

    公开(公告)号:WO2022215048A1

    公开(公告)日:2022-10-13

    申请号:PCT/IB2022/053322

    申请日:2022-04-08

    Abstract: The present invention refers to a process for the industrial-scale preparation of 17β-hydroxy- 6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21-carboxylic acid y-lactone, known by the common name of Drospirenone, in the form of a fine powder without the use of mechanical grinding or micronization techniques, but rather exploiting a double change of crystalline form, from Crystalline Form I to Crystalline Form II and from Crystalline Form II to Crystalline Form I. The invention also refers to the new Crystalline Form II of Drospirenone obtained in the process.

    PROCESS FOR THE PREPARATION OF ABIRATERONE OR ABIRATERONE ACETATE
    5.
    发明申请
    PROCESS FOR THE PREPARATION OF ABIRATERONE OR ABIRATERONE ACETATE 审中-公开
    制备阿维菌素或乙酸阿贝特龙的方法

    公开(公告)号:WO2015014686A1

    公开(公告)日:2015-02-05

    申请号:PCT/EP2014/065813

    申请日:2014-07-23

    CPC classification number: C07J43/003 C07J31/006

    Abstract: The present invention relates to a novel process for the synthesis of abiraterone and in particular abiraterone acetate, a compound of formula (I) reported below: having pharmacological activity suitable for slowing down the progression of advanced stage prostate cancer. The process is characaterised by the fact that the intermediate triflation step is carried out on prasterone (DHEA) or its 3-acetate using Ar-N(OTf) 2 as the triflation reagent, but where Ar is not phenyl, and by the fact that the base used in this step is an alkali metal alcoholate.

    Abstract translation: 本发明涉及一种用于合成阿维酮酮,特别是阿维昔龙醋酸酯的新方法,该方法报告如下:具有适于减缓晚期前列腺癌进展的药理学活性。 该方法的特征在于以下事实:中间三价充气步骤使用Ar-N(OTf)2作为三氟化试剂进行prasterone(DHEA)或其3-乙酸酯,但是Ar不是苯基,而事实上 该步骤中使用的碱是碱金属醇化物。

Patent Agency Ranking